Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MOVE | Movano | $16.53 | $9.56 | 137.16% | 998.3K | $6.3M | $4.67$55.00 |
| DRCT | Direct Digital | $4.02 | $1.71 | 74.06% | 98.9M | $3.0M | $1.58$80.85 |
| BNAI | Brand Engagement Network | $14.72 | $6.06 | 69.98% | 22.1M | $39M | $1.18$18.30 |
| QCLS | TNF Pharmaceuticals, Inc. | $5.62 | $1.55 | 38.08% | 13.3M | $17M | $2.50$137.99 |
| CHRS | Coherus Oncology | $2.06 | $0.47 | 29.56% | 13.1M | $192M | $0.71$2.17 |
| RVYL | Ryvyl | $6.73 | $1.49 | 28.45% | 11.6M | $5.4M | $4.50$81.55 |
| LIF | Life360 | $70.02 | $15.21 | 27.75% | 72.4K | $4.3B | $29.62$112.54 |
| GIBO | Gibo | $2.16 | $0.39 | 21.85% | 31.4M | $6.4M | $1.49$1,396.00 |
| ADAG | Adagene | $2.44 | $0.41 | 20.20% | 1.3M | $96M | $1.30$3.16 |
| STI | Solidion Technology | $9.59 | $1.48 | 18.25% | 81K | $61M | $2.94$33.99 |
Related Articles
Featured Article
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Alex Carchidi|Jun 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
Jia Jie Chen|Apr 21, 2021
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
This Was the Top-Performing IPO in 2020
Rick Munarriz|Dec 28, 2020
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
Up 1,600% In 2 Days, Is It Too Late To Buy This Hot Biotech Stock?
Zhiyuan Sun|Dec 10, 2020
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
Coherus BioSciences Keeps Proving Wall Street Wrong
Maxx Chatsko|Aug 11, 2020
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
2 Top Small-Cap Stocks to Buy Right Now
Maxx Chatsko|Jun 12, 2020
Volatile stock market or not, these two drug developers are well positioned for long-term success.
Is Coherus BioSciences a Buy?
Maxx Chatsko|May 26, 2020
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys
Maxx Chatsko|Apr 17, 2020
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
2 Top Small-Cap Stocks to Buy in December
Maxx Chatsko|Dec 10, 2019
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
Maxx Chatsko|Nov 19, 2019
The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
